The purpose of this study was to determine the safety and efficacy of filgrastim as an adjunct to induction and consolidation chemotherapy in poor risk patients with myelodysplastic syndrome (MDS). Filgrastim was given both during and after chemotherapy with the objective to accelerate hematopoietic repopulation and enhance the efficacy of chemotherapy. In a prospective randomized multicentre phase II trial, a total of 64 patients with poor risk primary MDS were randomized to receive either granulocyte colony-stimulating factor (G-CSF, filgrastim, AMGEN, Breda, The Netherlands) 5 g/kg/day subcutaneously or no G-CSF in addition to daunomycin (30 mg/m 2 /days 1, 2 and 3 intravenous bolus) and cytarabine (200 mg/m 2 days 1-7, continuous infusion). The overall complete response rate was 63%: 73% for patients receiving filgrastim as compared to 52% in the standard arm (P = 0.08). Overall survival at 2 years was estimated at 29% for patients assigned to the filgrastim arm and 16% for control patients (P = 0.22). The median time for recovery of granulocytes towards 1.0 × 10 9 /l post-chemotherapy was 23 days in the filgrastim-treated patients vs 35 days in the standard arm (P = 0.015). There were no differences in time of platelet recovery, length of hospital stay, duration of antibiotic use or infectious complications between the two treatment groups. However the earlier recovery of neutrophils in the filgrastim group was associated with a reduced interval of 9 days between the induction and consolidation cycle. In patients with poor risk MDS the use of filgrastim during and after induction therapy results in a significantly reduced neutrophil recovery time. Further study may be warranted to see if the apparent trend of the improved response to chemotherapy in combination with filgrastim can be confirmed in greater number of patients and to assess the effect of the addition of filgrastim on survival.
Introduction
The myelodysplastic syndromes (MDS) are characterized by refractory cytopenias with cellular dysfunction and a defective myeloid maturation of two or three hematopoietic cell lineages. 1 MDS has been estimated to be the most frequent hematological malignancy in the older age group. 2 A significant proportion of patients with MDS following progression of the disease develop acute myeloid leukemia. In approximately 20-40% of cases the cause of death relates to infection or bleeding. 3 A variety of treatment modalities has been used in MDS. Allogeneic stem cell transplantation is the only curative treatment but is only applicable in a minority of patients. 4 The clinical use of hematopoietic growth factors (HGFs), especially GM-CSF and G-CSF, applied without concomitant chemotherapy in MDS has been extensively studied. 5, 6 The use of these growth factors almost invariably leads to an increase in neutrophil count and may reduce the incidence of infections, however it has not been shown to result in improved treatment response or survival. Fortunately there seems to be no adverse influence on the rate of progression to AML. Intensive induction chemotherapy in patients with MDS as is applied in the treatment of AML may induce complete remissions (CR). However, on average, CR rates are lower than in AML. [7] [8] [9] Hematological recovery following induction therapy is usually characterized by polyclonal hematopoiesis, but the median remission duration is short (12 months) . Prolonged pancytopenia resulting in a greater hypoplastic death rate is one explanation for the reduced CR rate. Resistance to chemotherapy has also been argued to be responsible for treatment failure in MDS. 10 It has been assumed that HGFs are capable of reducing the duration of the pancytopenic period after chemotherapy, and therefore reducing infectious morbidity and mortality. In addition it has been argued, based upon preclinical evidence, that hematopoietic growth factors administered simultaneously with chemotherapy might prime the malignant cells to make them more susceptible to cell killing, and thus contribute to overcome drug resistance. 10, 11 Here we present the results of a randomized study which addressed the question as to whether the addition of G-CSF to remission induction chemotherapy might improve the hematopoietic recovery and response to chemotherapy and reduce the frequency and severity of infectious complications.
Materials and methods

Study design
Patients with poor risk myelodysplastic syndromes were randomized to receive either granulocyte colony-stimulating factor (G-CSF, filgrastim, AMGEN, Breda, The Netherlands) 5 g/kg/day subcutaneously or no G-CSF in addition to daunomycin (30 mg/m 2 /days 1, 2 and 3 intravenous bolus) and cytarabine (200 mg/m 2 days 1-7, continuous infusion). In case of a PR after the first induction cycle a second identical remission induction course was administered. Patients in CR after one or two cycles received one chemotherapy cycle for consolidation consisting of daunomycin (30 mg/m 2 /day 1 intravenous bolus) and cytarabine (200 mg/m 2 days 1-7, continuous infusion). The primary objective of the study was to assess the ability of G-CSF to reduce the time to recovery from neutropenia (ANC Ͼ1.0 × 10 9 /l) post-chemotherapy. The secondary endpoint was to assess the ability of G-CSF to improve the response rate of patients with MDS to induction chemotherapy.
Patients
Patients with poor risk primary MDS were eligible when they were between 18 and 75 years of age with adequate hepatic, renal and cardiac function and with ECOG performance scale 0, 1 or 2 after having given informed consent. Poor risk myelodysplastic syndrome was defined as (1) RAEB or CMML with either ANC Ͻ1.5 × 10 9 /l, platelets <30 × 10 9 /l or red blood cell transfusion requirements exceeding 3 units per 4 weeks; (2) RAEB-t. Risk classification was estimated according to the International Prognostic Scoring System for MDS(IPSS). 12 Patients were excluded if they had previously been treated with colony-stimulating factors, or presented with active uncontrolled infection. They were also ineligible in case of a second active primary neoplasm malignancy.
G-CSF (filgrastim)
Patients randomized to G-CSF (filgrastim) received the study drug at a dose of 5 g/kg/day once daily starting at day 0 (one day prior to the start of chemotherapy) and given during and after chemotherapy until neutrophil recovery (ANC Ͼ0.5 × 10 9 /l) occurred. G-CSF had to be discontinued immediately if during treatment evolution to acute myeloid leukemia or progression from RAEB/CMML to RAEB-t was observed and in case of serious toxicity considered to be attributable to G-CSF.
Supportive care
Decontamination of the gastro-intestinal tract was applied according to local protocols in the various centers. Empiric broad spectrum antibiotics were started in case of fever higher than 38.5°C. Prophylactic platelet transfusions were given when counts dropped below 20 × 10 9 /l. Therapeutic infusions were administered in case of active bleeding. Filtrated red blood cells were transfused to maintain the hematocrit above 30%.
Evaluation and statistical analysis
Complete remission (CR) was defined as a bone marrow which contains Ͻ5% blasts, no circulating blasts together with absence of extramedullary disease. After induction cycle II and consolidation cycle III recovery of peripheral blood values to platelets more than 100 × 10 9 /l and neutrophils of at least 1.5 × 10 9 /l was required as well. A partial response (PR) was defined as either one of three endpoints of improvement: a 50% decrease in blasts in patients who initially had an increased percentage of these cells (a), an increment of polymorphic neutrophils of at least 100% or more than 1 × 10 9 /l (b) or as an increment in platelet count of at least 100% or an increase of more than 50 × 10 9 /l (c). Failure of induction therapy was defined as absolute drug resistance, early death (before the completion of chemotherapy of the first induction cycle) or hypoplastic death.
Chromosomal abnormalities were described according to the International System for human Cytogenetics Nomenclature. Toxicity was evaluated according to ECOG criteria. Duration of neutropenia and thrombocytopenia was defined as the time, in days, from the start of chemotherapy until the day of the first measurement of ANC Ͼ1 × 10 9 /l and platelets Ͼ20 × 10 9 /l, respectively. Patients who died, progressed or were lost to follow-up were censored at the date when the last neutrophil or platelet count was measured. Overall survival (OS) was measured from the date of registration until death or last contact. Event-free survival (EFS) was measured from the date of registration until no CR, relapse after CR, death in CR or last contact whichever occurred first. In case a patient did not reach CR on protocol treatment, EFS was set at 0. Disease-free survival (DFS) was measured from attainment of CR until the date of relapse, death or last contact whichever occurred first. The number of days with fever, antibiotics used and the duration of hospital stay were evaluated separately. When the study was designed, there was no information available on the proportion of patients with neutrophil recovery. Therefore, the sample size calculation was based upon the difference between two means. It was assumed that the time to recovery of the neutrophil count would have a standard deviation of 5 days. In order to have a 90% chance of detecting a mean difference of 5 days or more, using a twosided test and a 5% significance level, 22 patients would be needed in each treatment arm. To allow for possible patient withdrawals from the study, it was intended to randomize 30 patients to each treatment group. That number would also enable estimation of the difference in response rate between the two treatment arms with a standard error of approximately 12%. Randomization was stratified by hospital.
The proportions of patients in the two treatment arms showing response on protocol treatment were compared using Pearson's chi-squared test, and the 95% confidence intervals for the difference in proportions was calculated. Differences between patient characteristics at the time of randomization were compared using Pearson's chi-squared test or Fisher's exact test. Univariate and multivariate logistic regression was used to see whether there was a difference of the response rates between subgroups.
Curves for overall survival (OS), event-free survival (EFS), disease-free survival (DFS) and hematological recovery were calculated using the actuarial method of Kaplan and Meier and were compared by the log-rank test. Univariate and multivariate Cox regression was used to determine prognostic factors for survival and recovery. Variables included in the analysis were: age, gender, FAB classification, blasts present in the peripheral blood (absent vs present), ECOG performance status and treatment (G-CSF vs no G-CSF). Patients with ECOG score 1 or 2 were grouped together for the analysis of prognostic factors. The patients with CMML were included in the group of patients with RAEB. All reported P values are twosided and a significance level ␣ = 0.05 was used.
Results
Patient characteristics
Between August 1992 and March 1995, 65 patients were registered and randomly assigned to one of the two treatment arms, ie filgrastim (n = 33) or no filgrastim (n = 32). One patient in the no filgrastim arm was considered ineligible and was excluded because the bone marrow sample on the day of registration was compatible with AML. Thus 33 patients received G-CSF (filgrastim) while 31 patients received induction chemotherapy without filgrastim. Clinical and hematological characteristics are listed in Table 1 . The median age of the patients was 62 years. There were no significant differences with regard to age, sex, FAB classification and blood counts between both treatment groups. Slightly more patients with ECOG performance status 1 were assigned to the arm with filgrastim. Cytogenetic studies were successfully performed in 44 patients, not done in two and were inadequate in 14 (Table 1) . Among the patients with cytogenetic abnormalities in eight cases a 5q−, in six cases a trisomy 8, in nine cases a monosomy 7 and in 13 cases complex abnormalities (involving two or more structural changes) were demonstrated. There are missing data in four other cases. Nine of the cytogenetic analyses were considered inadequate because NN was based on 10 metaphases only, they were used however for estimation of IPSS. Most of the patients were classified in the intermediate-2 and high risk category while only four were allocated in the intermediate-1 risk group (Table 1) . In nine patients risk classification could not be estimated accurately because of lacking data, however based on the existing data at least five of these patients would already be classified as intermediate-2 or higher while none of these nine would be classified as low risk. The delivered amounts of daunomycin and cytarabine were in close agreement with the protocol prescriptions with means of 99% and 98.5%, respectively. The mean dose of filgrastim applied with cycle I was 4.93 g/kg/day (range 3.98-6.58 g/kg/day). In five patients filgrastim was stopped early.
Hematological recovery
Hematological recovery was the primary endpoint of this study. We restricted the latter analysis to induction cycle I and consolidation cycle III because only four patients received induction cycle II.
Induction cycle I:
The median time to neutrophil recovery to 1.0 × 10 9 /l was significantly reduced in the filgrastim treated patients, 23 vs 35 days, P = 0.015) ( Table 2 and Figure 3 ). No significant difference was apparent with regard to platelet recovery between the two treatment groups ( Table 2 ). The median numbers of platelet transfusions following chemotherapy were nine (range 3-67) arm and eight (range 4-78) in the filgrastim and standard arm, respectively. The average number of red blood cell transfusions was 12 in both groups.
Consolidation cycle III:
Also following the consolidation cycle III, a considerable reduction in time to neutrophil recovery was apparent (median 24 vs 33 days, P = 0.058) while no difference in time reguired for platelet recovery was observed. The median duration between the start of the previous cycle and the start of the consolidation cycle was 45 days (range 27-62) in the filgrastim arm vs 52 days (range 34-79) in the control group. The numbers of red blood cells as well as platelet transfusions did not differ between the treatment groups. 
Response to chemotherapy
Forty patients (63%) attained a complete remission. The rate of complete remission among 33 patients assigned to receive filgrastim was 73% (24/33) as compared to 52% (16/31) in the other treatment arm, P = 0.08 9% CI (−2.6%, 44.8%). Seven patients achieved a PR after cycle I (Table 3) . Reasons for not obtaining CR or PR were mainly related to resistance to chemotherapy, prolonged hypoplasia, and early death (Table 3) . Seven patients who failed to achieve at least a PR after the first induction cycle did not receive a second cycle because of excessive toxicity (n = 5), pulmonary infection (n = 1) or refusal (n = 1). At 36 months, 32 of 40 complete responders had relapsed (79%) and four had died in continuous CR. The causes of nonleukemic deaths in the latter four individuals related to infectious complications (n = 3) and other toxicity (n = 1).
Survival
Overall survival at 1 year from randomization was 61% (standard error 9%) for patients on the G-CSF arm and 48% (s.e. 9%) for those on the standard arm, and at 2 years 29% (s.e. 8%) and 16% (s.e. 7%), respectively ( Figure 1 ). Despite
Figure 1
Overall survival of patients with MDS randomized to chemotherapy with or without G-CSF.
Figure 2
Disease-free survival from CR of patients with MDS randomized to chemotherapy with or without G-CSF.
a longer median overall survival in the filgrastim arm (16 vs 9 months), there was no significant difference between the two arms (P = 0.22). Because of the imbalance in ECOG score at randomization between the two treatment arms a log-rank test stratified by ECOG performance status was also performed, but this did not alter the conclusion (P = 0.62). Eventfree survival from randomization and disease-free survival (Figure 2 ) from CR at 12 months for all patients were 27% and 37%, with no difference between the two treatment arms (P = 0.13 and 0.42, respectively).
Univariate Cox regression showed that ECOG performance status 1 or 2 at diagnosis was the only negative prognostic factor for overall survival (P = 0.02), the hazard ratio compared to ECOG performance status 0 was 1.97 (95% CI 1.11, 3.51). ECOG performance status remained the only significant variable in the multivariate Cox regression when treatment arm was added. Finally, in the multivariate analysis when all six variables were included, gender (woman did better than men) and blasts in peripheral blood (absent was better than present) were also of borderline significance (P = 0.06) ( Table 4 ).
Figure 3
Neutrophil recovery above 1 × 10 9 /l after induction cycle I of patients with MDS randomized to chemotherapy with or without G-CSF. 
Toxicity
There were no notable differences with regards to cardiac, pulmonary, neurological, renal, cutaneous, and gastrointestinal toxicity among the two treatment groups. No significant difference of bleeding tendency in patients treated according to one of the protocol arms was observed. The median number of days with fever of patients on the filgrastim arm after cycle I was 6 (range 1-21) as compared to 7 (range 1-23) in the control group. There were no differences in length of hospital stay, duration of antibiotic use and frequency of serious infections (Table 5) .
Discussion
In recent years a variety of treatment approaches in MDS have been investigated. Supportive therapy with transfusion of appropriate blood components and antibiotic treatment is still the most common strategy. 13 Anecdotal successes with differentiation inducers and hormonal therapy have been described but they have not been reported to consistently improve longterm survival. 14, 15 Hematopoietic growth factors, without concomitant chemotherapy have been used with the objective of stimulating the differentiation of residual or leukemic cells. The use of both G-CSF and GM-CSF has led to an increase in neutrophils but with no or a minimal effect on anemia and trombocytopenia. 5, 6, 16 However, HGF treatment did not lead to an improvement of survival.
Two other mechanisms of growth factor therapy potentially leading to improvement of outcome of chemotherapy have been considered: (1) a reduction of the pancytopenic period in adjunct to chemotherapy; and (2) sensitizing of the malignant cells for cytotoxic agents by recruiting these cells into the cell cycle. 17 Remission induction chemotherapy, as is generally used in AML, may induce complete remissions in MDS in 15-64% of cases. [7] [8] [9] 18 Although CR rates vary widely between studies they appear to be lower as compared to those attained in patients with de novo AML. 19 In addition, remission duration is usually short (median less than 1 year). It has been suggested that the reasons for these reduced CR rates are related to: (1) drug resistance and (2) prolonged duration of pancytopenia resulting in high toxic death rates. This study was designed to investigate whether the addition of HGFs to chemotherapy would make the malignant clone more sensitive to the cytotoxic effects of the chemotherapeutic drugs and ameliorate the neutropenic period resulting in less frequent infectious complications in poor risk MDS. To the best of our knowledge this is the first prospective randomized trial exploring the value of AML-type therapy combined with HGFs applied during and after chemotherapy in poor risk MDS only. The CR rate of 63% in all patients is comparable to the average CR rate reported in elderly patients with AML. The difference in CR probability observed between the G-CSF arm (73%) and the standard arm (52%) was of borderline significance (P = 0.08). This difference is of particular note, considering the small sample size of this study. Further studies along this line appear of interest. Clearly this study with limited numbers of patients did not show a difference in survival between both treatment arms (P = 0.22). Up to now there are no other randomized studies in MDS in which the priming effects of HGFs on chemotherapy have been studied. In AML there are six published randomized studies as recently reviewed. 20 In most studies in which HGF (G-CSF or GM-CSF) were administered concomitantly with chemotherapy, they were continued untill neutrophil recovery. The conclusions of these studies are that there is no apparent improvement in CR rate by HGFs so that evidence for priming effect of HGFs on non-cycling cells could not be documented in AML.
In this study, the duration of neutropenia was significantly reduced in the G-CSF arm. Time to platelet recovery did not differ significantly. The shorter neutropenic period was not associated with a reduction of the infectious complications, a reduction of the use of antibiotic use or a shorter hospitalization period. An important observation in this study is that earlier neutrophil recovery in the G-CSF arm correlated with the start of the consolidation cycle, being 9 days earlier as compared to that in the control group. Perhaps the concentrated interval of delivery of induction and consolidation chemotherapy does explain the better response frequency among patients on the G-CSF treatment arm. No other comparable studies have been reported in MDS. The reduction of the time interval towards neutrophil recovery of 12 days (following induction) and 9 days (following consolidation) was of greater magnitude than has generally been reported in AML. In controlled studies in AML investigating the role of HGFs after induction chemotherapy a consistent reduction in duration of neutropenia varying from 2-13 days was observed. 20, 21 In those studies in patients with AML, beneficial effects of G-CSF or GM-CSF with respect to documented infections, hospital stay, antibiotic use and overall survival could not be documented. However, Rowe et al 22 showed an overall survival benefit, but in this study the control arm without GM-CSF showed an unusually poor outcome. In another AML study the reduction in duration of neutropenia was paralleled by statistically significant and clinically important reduction in the duration of fever, antibiotic use and hospitalization across all cycles of therapy. 23 Bernasconi et al 24 also showed that addition of G-CSF after chemotherapy in high risk MDS or secondary AML resulted in a shortened duration of neutropenia and better responses while no prolongation of CR duration or survival was noticed. One may wonder why such a significant reduction of the neutropenic period did not reduce morbidity or mortality. Two explanations emerge: (1) AML and MDS represent an older age group as compared to those patients who benefit from a shorter neutropenic period after chemotherapy and (2) patients with a myeloid malignancy often have been neutropenic for prolonged periods even before the start of induction chemotherapy. Infections most frequently occur early in the course of treatment before accelerated recovery of neutrophils could possibly influence the infectious episode. 25 There is no additional toxicity of G-CSF noted in this study, especially no unexpected numbers of patients experiencing a development to AML.
In conclusion, in this prospective randomized phase II study in patients with poor risk MDS, the addition of G-CSF to chemotherapy leads to a considerable and statistically significant shortening of the neutropenic period after induction therapy and a trend to a better response to chemotherapy. Future studies in greater number of patients appear warranted, to investigate whether the enhanced response rate were due to time-concentrated application of succesive induction and consolidation chemotherapy and whether the use of G-CSF might also effect survival outcome in these patients.
